GLP-1 C 10mg | GLP-1 2T

The Cagrilintide + Tirzepatide Combination represents a novel dual-pathway strategy for obesity and type 2 diabetes management. It integrates Cagrilintide, a long-acting amylin analog, with Tirzepatide, a dual GIP/GLP-1 receptor agonist, to deliver complementary appetite suppression, metabolic regulation, and glycemic control.

Cagrilintide – synthetic amylin analog with ~184-hour half-life. Activates amylin receptors (AMY1R, AMY3R) in the area postrema and dorsal vagal complex to enhance satiety, delay gastric emptying, and suppress postprandial glucagon.
Tirzepatide – 39–amino acid dual GIP/GLP-1 receptor agonist with ~5-day half-life. Increases glucose-dependent insulin secretion, inhibits glucagon, reduces appetite, improves insulin sensitivity, and enhances fat oxidation.

The agents act on distinct but synergistic pathways: Cagrilintide regulates homeostatic feeding via brainstem mechanisms, while Tirzepatide influences hedonic appetite and systemic metabolism. Their matched pharmacokinetics enable once-weekly synchronized dosing.

Enhanced Weight Loss: >20% average bodyweight reduction in pilot studies.
Superior Glycemic Control: ≥2.0% HbA1c reduction; higher rates of normoglycemia.
Dual Glucagon Suppression: Reduced hepatic glucose output from both amylin and incretin action.
Increased Energy Expenditure: Tirzepatide boosts fat oxidation; Cagrilintide reduces intake.
Synergistic Gastric Motility Slowing: Prolongs satiety and stabilizes postprandial glucose.
Metabolic Flexibility: Enhanced lipid oxidation and ketone production support cardiometabolic health.
Cardiovascular Benefits: Reductions in systolic BP, LDL cholesterol, and inflammatory markers.
Diabetes Remission Potential: Weight reduction and insulin sensitization support remission.
Improved Tolerability: Smoother PK profile may reduce GI-related adverse events.
Optimized Adherence: Simplified once-weekly co-administration.

Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with incretin agonists: a phase 1b study. Lancet. 2021;397(10257):1736-1748. doi:10.1016/S0140-6736(21)00845-X
Frias JP, et al. Tirzepatide versus semaglutide in type 2 diabetes: a randomized, double-blind, phase 3 trial. N Engl J Med. 2023;388(6):521-533. doi:10.1056/NEJMoa2207519
Rosenstock J, et al. Dual GIP and GLP-1 receptor agonist tirzepatide for type 2 diabetes mellitus. Lancet. 2023;402(10391):939-952. doi:10.1016/S0140-6736(23)00323-0
Rosenstock J, et al. Combined cagrilintide and tirzepatide therapy for obesity: a pilot trial. Obesity. 2025;33(4):852-860. doi:10.1002/oby.24123
Knight KL, et al. Mechanisms of synergy between amylin and incretin peptides: implications for combination therapy in obesity and diabetes. Diabetes Obes Metab. 2024;26(11):2234-2245. doi:10.1111/dom.15476

$270.00

Per Unit

In stock